Thank you for joining us today despite your busy schedule. I will present the FY 2025 first quarter results and the outlook for the first half. Page one shows the FX assumptions and actual results. The Q1 assumption was ¥152 against the dollar, but the actual was JPY 145, JPY 7 appreciation versus the plan. For FX assumption for the second quarter, we are assuming JPY 145 to the dollar. Page two shows the overview of the Q1 financial results. In the first quarter, net sales increased by JPY 6.3 billion to JPY 305.1 billion, with operating profit up by JPY 1 billion- JPY 21.2 billion. The blue stars indicate renewed record high figures. The ordinary profit was down due to the FX impact, and net income decreased due to smaller gains on sales of cross-shareholding sales. Page three shows the Q1 breakdown of net sales and operating profit by segment. In Q1, sales and operating profit grew substantially for the Housing company, both achieving record highs as first quarter numbers. The performance of the Housing business offset the decline in sales and profits of all other segments, enabling us to achieve a growth in sales and profits for the group as a whole. The JPY 900 million drop in operating profit for the HPP company in Q1 was caused by the one-off raw material expense related to a transaction in Europe. When adjusting for this, profit in effect grew for HPP. We have not disclosed their quarterly profit forecast, but consolidated operating profit is trending slightly above the plan. Page four is our outlook for market conditions. Auto production globally in the first quarter was in line with our April forecast. We expect production in Q2 to be slightly below the outlook. Q1 smartphone shipments were slightly above expectation, and for Q2, we expect it to be slightly below our forecast. The upper right shows the visitors for the Housing business. In Q1, both showroom visits and requests for information were down year- on- year. Although not indicated in the table, campaigns and referrals led to some increase, but the overall level was slightly below the previous year. As shown by the chart below, new housing stocks continue to decline, and the outlook for the first half is in line with the original projection. Domestic NAFTA prices are below our assumption, and we expect this trend to continue in Q2. Next on page five is the outlook for the first half. As shown at the bottom line of the table, total net sales are expected to be JPY 639.2 billion, up by JPY 10.1 billion, with operating profit of JPY 48.9 billion, an increase of JPY 0.2 billion. Both figures are expected to be record highs. By segment, we are aiming for record high sales and operating profit in the HPP and U I EP segments. Details of each segment will be explained later. The right side of the table shows the latest forecast against the plan. Despite the net sales projected to fall short of the plan, operating profit is expected to be on track. We believe that the direct impact of the U.S. tariff in the first half will be minimal. In another segment, we are making progress as planned in strengthening our production capacity for perovskite solar cells toward achieving 100 megawatts of production by FY 2027. Page 6 illustrates the by segment outlook for the first and second quarters. As indicated at the bottom of the table, the consolidated operating profit in Q1 grew by JPY 1 billion and is projected to drop by JPY 0.8 billion in Q2. By segment, the Housing company was significantly affected by the impact of leveling after the business fluctuation. Operating profit for HPP was down in Q1 due to the one-off raw material expense, but in Q2, we expect profit increase owing to growth in the mobility field, including interlayer films for head-up displays and the aerospace applications, expansion of spreads, and reduction of fixed costs. Page seven highlights factors affecting the outlook for the first half. Shown on the left, we expect net sales to be up by JPY 10.1 billion year- on- year. On the right is an analysis of factors affecting operating profit. The impact of volume and mix will increase by JPY 5.5 billion year- on- year. However, the contribution is expected to fall short of the plan due to stagnant market conditions in some areas of HP P and Medical business. In cost reduction, etc., on top of the temporary expense for HPP booked in Q1, additional costs will be incurred for repairs of specific products in UIEP in Q2, and as such, the contribution will be less than planned. Despite some negative FX impact, we expect total operating profit to grow by JPY 0.2 billion year on- year, in line with April outlook, owing to better margin and fixed cost reductions. Using page eight, I will explain the first half guidance and dividend. As mentioned on the previous page, net sales are expected to be JPY 639.2 billion, with operating profit of JPY 48.9 billion, both figures achieving record highs. Ordinary profit is expected to be up by JPY 1.6 billion to JPY 49.7 billion. Net profit is projected to decrease by JPY 7.8 billion year- on- year to JPY 35.1 billion due to lower gains from the sale of cross-shareholding sales. We intend a dividend hike of JPY 3- JPY 40 per share as planned as interim dividend. Starting from page nine, I will explain more details for each segment, starting with the first half outlook and analysis of the HPP company. The bar graph on the left shows sales of JPY 225.4 billion, an increase of JPY 4.3 billion. Due to the impact of a slowdown in certain markets, particularly in the mobility sector, sales are expected to fall short of the plan. On the right side is the analysis of OP. The volume and mix contribution will fall short of the plan, but will still increase by JPY 6.3 billion year- on- year. Despite the negative FX impact, we aim to achieve the first half guidance calling for OP of JPY 30.9 billion, a growth of JPY 1 billion year- on- year due to improvements in raw material prices and fixed cost reductions. Next, we would like to move on to page 10 for three strategic fields for HPP. Regarding electronics, we have seen firm large-scale display and smartphone trends in the LCD fields. We have seen an impact from inventory adjustment in certain semiconductor processing materials in the non-LCD field. However, we saw continued steady growth in other products such as functional foam tapes and heat release materials for semiconductor inspection equipment. In the middle is the mobility. This segment has been affected by the stagnant EV market. Sales of design interlayer films were particularly sluggish. However, sales of interlayer films for head-up displays grew steadily and are expected to exceed 130% on sales volume basis in the first half. Aerospace hit the break-even in the second half of the previous fiscal year and is contributing to earnings this fiscal year exceeding the plan. In the industrial on the right, domestic and overseas demand for construction and consumer goods is still sluggish, but will continue to focus on expanding sales of gross products by firmly maintaining the spread of sales price improvement that we have been working on since last year. Page 11 shows an overview of the first half of FY 2025 forecast for the Housing company. The first quarter had seen an increase in the number of new houses sold and unit prices in the Housing business, as well as increased order in the renovation business. On the left, net sales are projected to grow by JPY 5.9 billion to JPY 259.6 billion. As shown in the analysis of OP on the right, the number of houses sold will decrease by 210 in the second quarter, but the total OP in the first half is expected to increase by JPY 1.4 billion as planned, achieving the forecast of JPY 16 billion. Next, page 12. Left up shows the status of new housing orders. Although the market is still sluggish, the value of orders is growing steadily thanks to expanded sales of high-priced products such as apartment buildings. As shown in the bottom bar graph, the number of orders received in the first quarter was 95% year- on- year, but the value of orders received in the upper line represents 100% of the previous year's level. For the second quarter, we expect 96% in terms of volume and 101% for the value, and the total order amount for the first half is expected to be in line with the plan. Regarding the order by type of construction, apartment buildings in particular are growing steadily. The order backlog at the end of the fiscal year is expected to be JPY 160 billion, the same level as at the end of March. The red line on the upper right shows the increase in unit price per building. The unit price has been rising due to not only an increase in the installation rate of solar and storage batteries, but also due to an increase in the ratio of apartment buildings or higher value-added housing. Below left is the renovation orders. Steady progress in strengthening the sales training has ensured that maintenance demand from periodic inspections has been captured and growing. Sales in the real estate business in the middle of the bottom also grew steadily. The town and community development business in the lower right also performed well, with new sales of projects starting as planned. Page 13 shows an overview of the first half 2025 forecast for the UIEP company. Despite continued weak domestic housing and non-residential market conditions, by entrenching new prices, we project net sales to increase by JPY 1.5 billion to JPY 114.9 billion, and operating income to slightly increase to JPY 8.5 billion, expecting to make a record high number in the first half. Page 14 shows three strategic fields for the UIEP company. Pipe systems in the upper left. In the piping materials, the market remains sluggish, but we project growth in the second quarter on the back of an increase in prioritized product sales. CPVC, chlorinated polyvinyl chloride, despite the prolonged weak market conditions in India, a major demand center, we work to expand market share through new products. Upper right, building and infrastructure composite materials. For fire-resistant and non-flammable materials, we are continuing to acquire new customers. For FFU railway sleeper, we work to expand applications mainly in Europe. For prefabricated baths, we will focus on capturing nursing care and renovation demand. Bottom left is infrastructure renovation. For the pipeline renewal, surveys of aging sewer pipes are progressing, and we will work to acquire new orders, although the contribution will not be seen until the second half. In the aqua system, we continue to focus on large-scale plant equipment and facilities, as well as water storage panel tank orders. Right bottom are indices for priority initiatives. As for the prioritized product sales, we expect growth mainly in polyethylene pipes and fire-resistant pipes. For overseas, although we are affected by the sluggish Indian market, we expect growth in Europe, mainly in FFU. Page 15 is medical business. In the medical business, sales of mainstay pharmaceutical ingredient grew, but the diagnostic sales are projected to drop by JPY 2.1 billion to JPY 45.8 billion due to sluggish demand for infectious disease testing kits in Japan and overseas, and deteriorating market conditions in China. The right side shows the analysis of operating profit, which is affected by a decrease in demand and shipments of infectious disease testing kits in the U.S., and the worsening of the Chinese market due to measures to curb medical expenses. Despite efforts to control fixed costs, we have made a downward revision of the operating profit plan. We forecast JPY 5.3 billion, down by JPY 0.7 billion year- over- year. Page 16 is an overview by sub-business segment for medical business. Top left is domestic diagnostic business. We launched new coagulation devices in Q1. We work to expand sales of reagents. Top right is overseas diagnostics business, whose results were lower than expected in the U.S. and China. As a response to preferential measures for made-in-China products, we plan to launch new coagulation devices manufactured in China in the second half. To that end, we will make steady preparations in the second quarter. In the pharmaceutical sciences business, we are observing firm trends in mainstay pharmaceutical ingredient and drug development solution orders. Bottom right shows the sales of infectious disease testing kits, which are usually sluggish in the first quarter. We expect the sales to fall slightly short of the plan in this first half as well. We'll continue to focus on sales expansion, and that's all from myself. Thank you very much.